Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on November 1 and set a price target ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker ...

DelveInsight's Neurological Biomarkers Market Insights report provides the current and forecast market analysis, individual leading neurological biomarkers companies' market shares, challenges, ...